Kristine Cooper
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kristine Cooper has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Adam Chatoff
Aging + Cardiovascular Discovery Center, Department of Cardiovascular Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, USA
39 shared publications - Aidan R. Cole
Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
39 shared publications - Amandine Amalric
Molecular and Cellular Oncogenesis Program, Ellen and Ronald Caplan Cancer Center, The Wistar Institute, Philadelphia, PA, USA
39 shared publications - Apoorva Uboveja
Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, USA
39 shared publications - Baixue Yang
Department of Pharmacology and Chemical Biology and UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
39 shared publications - Claudia Veronica Da Silva Crispim
Aging and Cardiovascular Discovery Center, Department of Cardiovascular Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA
39 shared publications
Latest Publications
- Open Access
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from TGFβ Inhibition during Radiotherapy Enhances Immune Cell Infiltration and Decreases Metastases in Ewing Sarcoma
Radiotherapy modulates the Ewing sarcoma transcriptional profile in an immune contexture–dependent manner. A, Experimental overview of Ewing sarcomas established in hu-CD34+ and NSG mouse models followed by treatment with radiotherapy. B, RNA was extracted from tumors at the experiment termination and bulk RNA-seq was performed. Volcano plots demonstrating differential gene expression after radiotherapy of TC32 Ewing tumors developed in hu-CD34+ or NSG mice. n = 9 humanized mice and n = 6 NSG mice. C, Venn diagram depicting the number of significantly DEGs after radiotherapy when Ewing sarcoma tumors are developed in a hu-cD34+ vs. NSG model. D, Pathway analysis performed on the shared DEGs after radiation in immunocompetent mouse model utilizing the EnrichR bioplanet 2019 library. E, Upstream analysis utilizing IPA performed on shared gene lists identifies IFNγ and IRF3 as predicted upstream regulators. [A, Created in BioRender. Daley, J. (2025) https://BioRender.com/a3auqlx.]
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from TGFβ Inhibition during Radiotherapy Enhances Immune Cell Infiltration and Decreases Metastases in Ewing Sarcoma
Radiotherapy modulates the Ewing sarcoma transcriptional profile in an immune contexture–dependent manner. A, Experimental overview of Ewing sarcomas established in hu-CD34+ and NSG mouse models followed by treatment with radiotherapy. B, RNA was extracted from tumors at the experiment termination and bulk RNA-seq was performed. Volcano plots demonstrating differential gene expression after radiotherapy of TC32 Ewing tumors developed in hu-CD34+ or NSG mice. n = 9 humanized mice and n = 6 NSG mice. C, Venn diagram depicting the number of significantly DEGs after radiotherapy when Ewing sarcoma tumors are developed in a hu-cD34+ vs. NSG model. D, Pathway analysis performed on the shared DEGs after radiation in immunocompetent mouse model utilizing the EnrichR bioplanet 2019 library. E, Upstream analysis utilizing IPA performed on shared gene lists identifies IFNγ and IRF3 as predicted upstream regulators. [A, Created in BioRender. Daley, J. (2025) https://BioRender.com/a3auqlx.]
- Open Access
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from TGFβ Inhibition during Radiotherapy Enhances Immune Cell Infiltration and Decreases Metastases in Ewing Sarcoma
Figure S7. Bulk RNA sequencing was performed on TC32 Ewing sarcoma tumors developed in either hu-CD34+ or NSG mouse models.
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from TGFβ Inhibition during Radiotherapy Enhances Immune Cell Infiltration and Decreases Metastases in Ewing Sarcoma
Figure S7. Bulk RNA sequencing was performed on TC32 Ewing sarcoma tumors developed in either hu-CD34+ or NSG mouse models.
- Open Access
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from TGFβ Inhibition during Radiotherapy Enhances Immune Cell Infiltration and Decreases Metastases in Ewing Sarcoma
Immune cell infiltrates in human tumors
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from TGFβ Inhibition during Radiotherapy Enhances Immune Cell Infiltration and Decreases Metastases in Ewing Sarcoma
Immune cell infiltrates in human tumors
- Open Access
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from TGFβ Inhibition during Radiotherapy Enhances Immune Cell Infiltration and Decreases Metastases in Ewing Sarcoma
Ewing sarcomas developed in the hu-CD34+ model are biologically and transcriptionally distinct from tumors developed in an immunodeficient model. A, Orthotopic Ewing sarcomas are successfully established in a humanized (hu-CD34+) mouse. B, Representative CD99 and NKX2.2 IHC staining of Ewing sarcomas developed in a hu-CD34+ model, shown with a magnification of 200×. C, Representative CD99 and NKX2.2 IHC staining of lung metastases that developed in the hu-CD34+ Ewing sarcoma model, shown with a magnification of 200×. D, Immunophenotyping performed on peripheral blood mononuclear cells obtained from mice bearing TC32 Ewing sarcoma tumors at euthanasia following tumor growth demonstrates persistence of engrafted human immune cells. HuCD45 represents % of all peripheral lymphocytes that are huCD45 positive. The remaining cells that are hu-CD45 negative represent (defective) peripheral blood mononuclear cells of mouse origin. The percent of hu-CD45 cells that express CD20, CD3, and CD33 (representing B cells, T cells, and myeloid cells, respectively) is shown. n = 36 mice. Error bars represent SD. E, Representative flow cytometry plot demonstrates low (1.24% of all cells in the tumor) baseline huCD45+ infiltration in Ewing sarcomas developed in hu-CD34+ mice. F, Schematic depicting hu-CD34+ vs. NSG mouse models used in these experiments. G, Bilateral lungs were harvested from hu-CD34+ or NSG mice harboring TC32 Ewing sarcoma tumors, and the presence of metastatic foci per section was determined by an independent pathologist. Each bar represents average number of metastatic lesions per slide in individual mouse. ***, P < 0.001. Error bars represent SD. A t test was performed. n = 9 humanized mice and n = 6 NSG mice. H, Volcano plot of DEGs in TC32 tumors established in hu-CD34+ mice vs. NSG mice. I, Tumors were established (TC32 cell line) in hu-CD34+ or NSG mice. Time from tumor injection to survival was determined using pre-specified end points for survival (see “Materials and Methods”). Kaplan–Meier estimate was used for analysis. N = 7 and N = 9 for Hu-CD34+ and NSG, respectively. ns = P value ≥ 0.05. [F, Created in BioRender. Bailey, K. (2025) https://BioRender.com/4jtlo4v.]
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from TGFβ Inhibition during Radiotherapy Enhances Immune Cell Infiltration and Decreases Metastases in Ewing Sarcoma
Ewing sarcomas developed in the hu-CD34+ model are biologically and transcriptionally distinct from tumors developed in an immunodeficient model. A, Orthotopic Ewing sarcomas are successfully established in a humanized (hu-CD34+) mouse. B, Representative CD99 and NKX2.2 IHC staining of Ewing sarcomas developed in a hu-CD34+ model, shown with a magnification of 200×. C, Representative CD99 and NKX2.2 IHC staining of lung metastases that developed in the hu-CD34+ Ewing sarcoma model, shown with a magnification of 200×. D, Immunophenotyping performed on peripheral blood mononuclear cells obtained from mice bearing TC32 Ewing sarcoma tumors at euthanasia following tumor growth demonstrates persistence of engrafted human immune cells. HuCD45 represents % of all peripheral lymphocytes that are huCD45 positive. The remaining cells that are hu-CD45 negative represent (defective) peripheral blood mononuclear cells of mouse origin. The percent of hu-CD45 cells that express CD20, CD3, and CD33 (representing B cells, T cells, and myeloid cells, respectively) is shown. n = 36 mice. Error bars represent SD. E, Representative flow cytometry plot demonstrates low (1.24% of all cells in the tumor) baseline huCD45+ infiltration in Ewing sarcomas developed in hu-CD34+ mice. F, Schematic depicting hu-CD34+ vs. NSG mouse models used in these experiments. G, Bilateral lungs were harvested from hu-CD34+ or NSG mice harboring TC32 Ewing sarcoma tumors, and the presence of metastatic foci per section was determined by an independent pathologist. Each bar represents average number of metastatic lesions per slide in individual mouse. ***, P < 0.001. Error bars represent SD. A t test was performed. n = 9 humanized mice and n = 6 NSG mice. H, Volcano plot of DEGs in TC32 tumors established in hu-CD34+ mice vs. NSG mice. I, Tumors were established (TC32 cell line) in hu-CD34+ or NSG mice. Time from tumor injection to survival was determined using pre-specified end points for survival (see “Materials and Methods”). Kaplan–Meier estimate was used for analysis. N = 7 and N = 9 for Hu-CD34+ and NSG, respectively. ns = P value ≥ 0.05. [F, Created in BioRender. Bailey, K. (2025) https://BioRender.com/4jtlo4v.]
- Open Access
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S19 from TGFβ Inhibition during Radiotherapy Enhances Immune Cell Infiltration and Decreases Metastases in Ewing Sarcoma
Figure S19. TGFβ signaling is decreased in tumors of mice that receive RER following radiation therapy as compared to mice that are treated with radiation therapy (RT) alone.
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S19 from TGFβ Inhibition during Radiotherapy Enhances Immune Cell Infiltration and Decreases Metastases in Ewing Sarcoma
Figure S19. TGFβ signaling is decreased in tumors of mice that receive RER following radiation therapy as compared to mice that are treated with radiation therapy (RT) alone.
- Open Access
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Data from TGFβ Inhibition during Radiotherapy Enhances Immune Cell Infiltration and Decreases Metastases in Ewing Sarcoma
Ewing sarcoma is an aggressive cancer diagnosed in adolescents and young adults. Inhibition of TGFβ is being tested in limited clinical trials for relapsed Ewing sarcoma. TGFβ is an immunosuppressive cytokine that exists in latent and active states. The functional impact of TGFβ inhibition on the Ewing tumor microenvironment (TME) and on Ewing tumor behavior remains largely unknown. In this study, we use single-cell RNA sequencing analysis of human Ewing tumors to demonstrate that immune cells are the largest contributors of TGFB1 expression in the human Ewing TME. We utilize a humanized mouse model of Ewing sarcoma to demonstrate that TME signatures in these models differ significantly from Ewing sarcoma tumors developed in immunodeficient mice. Using this humanized model, we investigate the effect of TGFβ inhibition on the Ewing sarcoma TME during radiotherapy, a treatment that is commonly used to treat unresectable, metastatic, and relapsed/refractory Ewing sarcoma that is known to enhance TGFβ activation in multiple cancers. Utilizing a trivalent ligand TGFβ trap to inhibit TGFβ, we demonstrate that in combination with radiotherapy, TGFβ inhibition both increases Ewing sarcoma immune cell infiltration and decreases lung metastatic burden in vivo. These data demonstrate the value of immunocompetent models to address immune-biological preclinical questions in Ewing sarcoma and demonstrate that TGFβ inhibition during radiotherapy is a promising strategy to enhance antitumor immune response and improve treatment efficacy for metastatic Ewing sarcoma.Significance:This work demonstrates the importance of disrupting immunosuppression during radiotherapy to reduce lung metastatic potential in Ewing sarcoma. Humanized mouse models of Ewing sarcoma are also established as an immunocompetent preclinical tool to ask therapeutic questions about the Ewing TME.
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from TGFβ Inhibition during Radiotherapy Enhances Immune Cell Infiltration and Decreases Metastases in Ewing Sarcoma
Ewing sarcoma is an aggressive cancer diagnosed in adolescents and young adults. Inhibition of TGFβ is being tested in limited clinical trials for relapsed Ewing sarcoma. TGFβ is an immunosuppressive cytokine that exists in latent and active states. The functional impact of TGFβ inhibition on the Ewing tumor microenvironment (TME) and on Ewing tumor behavior remains largely unknown. In this study, we use single-cell RNA sequencing analysis of human Ewing tumors to demonstrate that immune cells are the largest contributors of TGFB1 expression in the human Ewing TME. We utilize a humanized mouse model of Ewing sarcoma to demonstrate that TME signatures in these models differ significantly from Ewing sarcoma tumors developed in immunodeficient mice. Using this humanized model, we investigate the effect of TGFβ inhibition on the Ewing sarcoma TME during radiotherapy, a treatment that is commonly used to treat unresectable, metastatic, and relapsed/refractory Ewing sarcoma that is known to enhance TGFβ activation in multiple cancers. Utilizing a trivalent ligand TGFβ trap to inhibit TGFβ, we demonstrate that in combination with radiotherapy, TGFβ inhibition both increases Ewing sarcoma immune cell infiltration and decreases lung metastatic burden in vivo. These data demonstrate the value of immunocompetent models to address immune-biological preclinical questions in Ewing sarcoma and demonstrate that TGFβ inhibition during radiotherapy is a promising strategy to enhance antitumor immune response and improve treatment efficacy for metastatic Ewing sarcoma.Significance:This work demonstrates the importance of disrupting immunosuppression during radiotherapy to reduce lung metastatic potential in Ewing sarcoma. Humanized mouse models of Ewing sarcoma are also established as an immunocompetent preclinical tool to ask therapeutic questions about the Ewing TME.
- Open Access
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S10 from TGFβ Inhibition during Radiotherapy Enhances Immune Cell Infiltration and Decreases Metastases in Ewing Sarcoma
Figure S10. Ewing sarcoma tumor growth is similar in humanized and NSG mouse models.
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from TGFβ Inhibition during Radiotherapy Enhances Immune Cell Infiltration and Decreases Metastases in Ewing Sarcoma
Figure S10. Ewing sarcoma tumor growth is similar in humanized and NSG mouse models.
- Open Access
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S16 from TGFβ Inhibition during Radiotherapy Enhances Immune Cell Infiltration and Decreases Metastases in Ewing Sarcoma
Figure S16. Survival of mice treated with ± RER and ± radiation therapy.
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S16 from TGFβ Inhibition during Radiotherapy Enhances Immune Cell Infiltration and Decreases Metastases in Ewing Sarcoma
Figure S16. Survival of mice treated with ± RER and ± radiation therapy.
- Open Access
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from TGFβ Inhibition during Radiotherapy Enhances Immune Cell Infiltration and Decreases Metastases in Ewing Sarcoma
Figure S5. Negative control tissue for CD99 and NKX2.2 staining.
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from TGFβ Inhibition during Radiotherapy Enhances Immune Cell Infiltration and Decreases Metastases in Ewing Sarcoma
Figure S5. Negative control tissue for CD99 and NKX2.2 staining.
- Open Access
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from TGFβ Inhibition during Radiotherapy Enhances Immune Cell Infiltration and Decreases Metastases in Ewing Sarcoma
The trivalent ligand trap (RER) effectively depletes TGFβ in vivo.A, Schematic of the mechanism of action of TGFβ1 ligand trap RER and interaction with TGBRII receptor. B, Comparison of TGFβ1 levels in the serum of mice at the time of sacrifice after receiving intraperitoneal injections of RER or PBS vehicle control. ***, P < 0.001. Error bars represent SD. A t test was performed for statistical analysis. C, Bulk RNA-seq was performed on tumors developed in hu-CD34+ mice that underwent treatment with radiotherapy on day 1 and received either RER or PBS on days 1 to 6. IPA performed on DEGs in tumors from mice receiving RER during radiotherapy demonstrates that TGFB1 is predicted to be inhibited upstream of the DEGs. Genes in the outer circle are differentially expressed; blue lines indicate the genes for which downregulation predicts TGFB1 inhibition.
- 27 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from TGFβ Inhibition during Radiotherapy Enhances Immune Cell Infiltration and Decreases Metastases in Ewing Sarcoma
The trivalent ligand trap (RER) effectively depletes TGFβ in vivo.A, Schematic of the mechanism of action of TGFβ1 ligand trap RER and interaction with TGBRII receptor. B, Comparison of TGFβ1 levels in the serum of mice at the time of sacrifice after receiving intraperitoneal injections of RER or PBS vehicle control. ***, P < 0.001. Error bars represent SD. A t test was performed for statistical analysis. C, Bulk RNA-seq was performed on tumors developed in hu-CD34+ mice that underwent treatment with radiotherapy on day 1 and received either RER or PBS on days 1 to 6. IPA performed on DEGs in tumors from mice receiving RER during radiotherapy demonstrates that TGFB1 is predicted to be inhibited upstream of the DEGs. Genes in the outer circle are differentially expressed; blue lines indicate the genes for which downregulation predicts TGFB1 inhibition.